GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
Follow GTBP
GT Biopharma, Inc. (GTBP) Altman Z-score
GT Biopharma, Inc.'s Altman Z-score for fiscal 2015 is −5138.41, in the distress zone (below 1.81).
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2015 | −5138.41 | — |
How fiscal 2015’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (923.33) | — | −1108.00 | |
| Retained earnings / total assets | (2,489.20) | — | −3484.89 | |
| EBIT / total assets | (165.81) | — | −547.19 | |
| Market value of equity / total liabilities | 1.93 | — | 1.16 | |
| Sales / total assets | 0.50 | — | 0.50 | |
| Altman Z-score | Distress zone | −5138.41 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −15287.20 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| VAXX Vaxxinity, Inc. compare | 3.3× |
| TVRD Tvardi Therapeutics, Inc. compare | −5.1× |
| DARE Dare Bioscience, Inc. compare | −8.9× |
| ADAPY Adaptimmune Therapeutics PLC compare | −23.3× |
| MRKR MARKER THERAPEUTICS, INC. compare | −28.7× |
| CNSY Cerenome, Inc. compare | −44.9× |
| GTBP GT Biopharma, Inc. | −5,138× |
| AKTX Akari Therapeutics PLC compare | — |
| NCEL NewcelX Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets